Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease

Oncotelic Therapeutics closed a strategic asset transfer with Lunai Bioworks, granting worldwide rights to its N2B nose-to-brain delivery system for biodefense and Alzheimer’s disease applications. In exchange, Oncotelic received $12.5 million in Lunai Series B Convertible Preferred Stock, while retaining rights to develop the N2B platform for other indications such as Parkinson’s disease.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.